Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the ...
Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this ...
The panel ensures compatibility with our previous autosomal Family Finder tests plus all the autosomal transfers we ...
Market Outlook and Growth TrajectoryThe global next generation sequencing market is poised to experience robust expansion, ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results